Table 2 Characteristics of five reported DI-MDS cases and the presented two cases
Reference | Age (years) | MDS subtype | Partial/complete deletion of chromosome 7 | MRI abnormal | Treatment of MDS | Outcome of CDI | Time to AML (months) | OS (months) |
|---|---|---|---|---|---|---|---|---|
Case 1 | 43 | RAEB1 | Yes | A slightly thickened pituitary stalk and a small nodule in the left pituitary | Allo-HCT | Controlled by desmopressin and cured after HCT | No | 13 + |
Case 2 | 40 | RAEB1 | Yes | No | Decitabine and Allo-HCT | Controlled by desmopressin and HCT, reappeared when disease progress | 2 | 11 |
4 | 74 | RAEB 1 | Yes | No | Supportive care | Controlled by desmopressin | 2 | 2 |
6 | 6 | RAEB 1 | Yes | No | Allo-HCT | Controlled by desmopressin and cured after HCT | No | NA |
7 | 53 | RAEB 2 | No (Norma karyotype) | Nodular lesion on pituitary stalk & absent of posterior “bright spot” of neurohypophysis on T1-weighed MRI | Chemotherapy and Allo-HCT | Controlled by desmopressin and need for desmopressin persists after allo-HCT | No | 18 + |
9 | 60 | MDS-MLD | No (Norma karyotype) | Attenuation of “bright spot” | Chemotherapy | Recovered after chemotherapy | 1 | NA |
10 | 73 | NA | Yes | Absent of posterior “bright spot” & symmetrical enhancing lesions in the hypothalamus | NA | Temporary controlled by desmopressin | 3 | 3 |